30-year Gilead R&D vet Nor­bert Bischof­berg­er is start­ing over as staffer #5 at an up­start biotech — and he’s ...

8 years ago
People
Startups

Cara hauls in $70M on first leg of glob­al deal, set­ting up PhI­II kid­ney dis­ease drug for com­mer­cial roll out

8 years ago
R&D
Pharma

Ver­sant backs new ap­proach to gam­ma delta T cells, co-leads Lava's $18.9M round

8 years ago
Financing
Startups

House pass­es 'right-to-try' — al­low­ing the ter­mi­nal­ly ill to ask com­pa­nies for ex­per­i­men­tal drugs out­side of FDA's ...

8 years ago
Pharma

FDA chief Got­tlieb is build­ing a reg­u­la­to­ry speed­way to ac­cel­er­ate gene ther­a­py de­vel­op­ment

8 years ago
Pharma
Cell/Gene Tx

Take­da bags $280M, sells off its stake in a Chi­na drug JV ahead of $62B Shire buy­out

8 years ago
Deals

Gates Foun­da­tion, UK gov­ern­ment back CARB-X, boost an­tibi­otics fund­ing past $500M

8 years ago
News Briefing

Fight­ing for a place in the ul­cer­a­tive col­i­tis mar­ket, Sub­lim­i­ty rais­es $64M for an al­ter­na­tive drug to an­ti-TNF

8 years ago
Financing

Sesen's PhI­II blad­der can­cer da­ta send stock south as in­vestors fret over safe­ty

8 years ago
R&D

Al­ler­gan dou­bles down on NM­DA de­pres­sion drug de­vel­op­ment ef­forts, bag­ging an op­tion to a small mol­e­cule fol­lowup ...

8 years ago
R&D
Pharma

Buoyed by he­mo­phil­ia A gene ther­a­py up­date, Bio­Marin switch­es to head-to-head study -- but shares slide on dura­bil­i­ty ...

8 years ago
R&D

Grail hauls in mon­ster $300M round from Chi­nese in­vestors amid ru­mors about Hong Kong IPO

8 years ago
Financing
China

New­com­er Do­va hus­tles a phar­ma castoff through to an FDA ap­proval, shares sink any­way

8 years ago
Pharma

Hunt­ing a cure, Spark re­ports steady progress on he­mo­phil­ia B gene ther­a­py as Pfiz­er preps for piv­otal hand­off

8 years ago
R&D

Wrestling with set­backs, Cel­gene adds $65M dis­cov­ery al­liance with Evotec to beef up on new can­cer drugs

8 years ago
R&D
Pharma

Bay Area start­up Rain Ther­a­peu­tics nabs $18M Se­ries A to tar­get lung can­cer niche

8 years ago
Financing
Startups

GSK gets Eu­ro­pean OK for HIV drug Ju­lu­ca; Akari dealt non-com­pli­ance no­tice from Nas­daq

8 years ago
News Briefing

BD chief George Golumbes­ki is the lat­est top ex­ec to ex­it Cel­gene dur­ing man­age­ment over­haul

8 years ago
People

Long side­lined on man­u­fac­tur­ing penal­ties, As­traZeneca fi­nal­ly gets a green light for a po­ten­tial hy­per­kalemia ...

8 years ago
Pharma

Nabri­va goes 2 for 2 in Phase III an­tibi­ot­ic pro­gram, scor­ing on a key cat­a­lyst -- but shares plunge on safe­ty ...

8 years ago
R&D

Roche adds a stel­lar round of piv­otal da­ta on Hem­li­bra, look­ing to ex­pand its mar­ket for a po­ten­tial mega-block­buster

8 years ago
R&D

An­oth­er cheap, old drug is be­ing fresh­ened up for brand pric­ing in the US — and shares soar, briefly

8 years ago
Bioregnum
R&D

As­traZeneca drops or di­vests a slate of drugs in lat­est quar­ter­ly up­date; Pierre Fab­re ex­tends a di­ag­nos­tic ...

8 years ago
News Briefing

Ag­ile bris­tles af­ter FDA's third snub, promis­ing a fight for its con­tra­cep­tive

8 years ago
R&D
First page Previous page 1034103510361037103810391040 Next page Last page
A service from the Financial Times